--- title: "Mirabegron: Dosing & Vendor Prices — BodyHackGuide" description: "Mirabegron: dosing protocols, mechanism & side effects. Compare 1 verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Mirabegron" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "Mirabegron", "description": "Mirabegron is an approved prescription drug, not a research chemical. Astellas Pharma developed it as YM-178 and it was approved by the FDA in 2012 under the brand name Myrbetriq for overactive bladder, with European approval as Betmiga; the US label now also covers neurogenic detrusor overactivity in children aged three and older. It works by activating the beta-3 adrenergic receptor, which relaxes the bladder detrusor muscle. The reason it appears on the research chemical market has nothing to do with bladders. Beta-3 receptors are also the main adrenergic receptors on rodent brown fat, and for decades beta-3 agonists were the leading candidate for a drug that would burn calories by turning on brown adipose tissue. Mirabegron was the first beta-3 agonist available in a form that could test that idea in people. The first test worked. In twelve healthy men, a single oral dose increased brown fat metabolic activity measured by FDG PET-CT in every subject and raised resting metabolic rate by 203 kcal per day, about 13 percent (PMID: 25565203). A four-week open-label study in 14 healthy women found higher brown fat activity and resting energy expenditure with no change in body weight or composition, alongside higher HDL cholesterol, apolipoprotein A-I, adiponectin and improved insulin sensitivity on an intravenous glucose tolerance test (PMID: 31961826). The complication is dose and receptor selectivity. A Canadian group showed that human brown adipocyte thermogenesis is actually driven by the beta-2 receptor, not beta-3, and that mirabegron only raised brown fat thermogenesis when taken at the maximum allowable dose, at which point it also bound beta-1 and beta-2 receptors, producing cardiovascular effects and white fat lipolysis (PMID: 32755608). A meta-analysis of six human studies found increased brown fat activity, resting energy expenditure, body temperature and free fatty acids, but also increased heart rate, diastolic blood pressure and insulin, with no change in brown fat volume or blood glucose (PMID: 38159219). Pharmacology is well characterized because it is a licensed drug. Plasma concentrations peak at three to five hours and decline with a terminal half-life of roughly 32 to 60 hours across two phase 1 studies; exposure is about 40 percent higher in women than men, and steady state is reached within a week (PMID: 23063375). Absorption, metabolism and excretion have been mapped with radiolabeled drug (PMID: 22269146). Anyone taking mirabegron for metabolic reasons is using an approved drug off-label at or near its ceiling dose, where the cardiovascular effects are real and measured. That is a different risk profile from its licensed bladder use, and it needs a prescriber, not a supplier.", "url": "https://www.bodyhackguide.co/compound/mirabegron", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "99.99", "highPrice": "99.99", "priceCurrency": "USD", "offerCount": "1", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "99.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/mirabegron/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" }, "name": "Mirabegron 3000mg capsule" } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Mirabegron", "description": "Mirabegron is an approved prescription drug, not a research chemical. Astellas Pharma developed it as YM-178 and it was approved by the FDA in 2012 under the brand name Myrbetriq for overactive bladder, with European approval as Betmiga; the US label now also covers neurogenic detrusor overactivity in children aged three and older. It works by activating the beta-3 adrenergic receptor, which relaxes the bladder detrusor muscle. The reason it appears on the research chemical market has nothing to do with bladders. Beta-3 receptors are also the main adrenergic receptors on rodent brown fat, and for decades beta-3 agonists were the leading candidate for a drug that would burn calories by turning on brown adipose tissue. Mirabegron was the first beta-3 agonist available in a form that could test that idea in people. The first test worked. In twelve healthy men, a single oral dose increased brown fat metabolic activity measured by FDG PET-CT in every subject and raised resting metabolic rate by 203 kcal per day, about 13 percent (PMID: 25565203). A four-week open-label study in 14 healthy women found higher brown fat activity and resting energy expenditure with no change in body weight or composition, alongside higher HDL cholesterol, apolipoprotein A-I, adiponectin and improved insulin sensitivity on an intravenous glucose tolerance test (PMID: 31961826). The complication is dose and receptor selectivity. A Canadian group showed that human brown adipocyte thermogenesis is actually driven by the beta-2 receptor, not beta-3, and that mirabegron only raised brown fat thermogenesis when taken at the maximum allowable dose, at which point it also bound beta-1 and beta-2 receptors, producing cardiovascular effects and white fat lipolysis (PMID: 32755608). A meta-analysis of six human studies found increased brown fat activity, resting energy expenditure, body temperature and free fatty acids, but also increased heart rate, diastolic blood pressure and insulin, with no change in brown fat volume or blood glucose (PMID: 38159219). Pharmacology is well characterized because it is a licensed drug. Plasma concentrations peak at three to five hours and decline with a terminal half-life of roughly 32 to 60 hours across two phase 1 studies; exposure is about 40 percent higher in women than men, and steady state is reached within a week (PMID: 23063375). Absorption, metabolism and excretion have been mapped with radiolabeled drug (PMID: 22269146). Anyone taking mirabegron for metabolic reasons is using an approved drug off-label at or near its ceiling dose, where the cardiovascular effects are real and measured. That is a different risk profile from its licensed bladder use, and it needs a prescriber, not a supplier.", "lastReviewed": "2026-09-07T04:47:49.328Z", "url": "https://www.bodyhackguide.co/compound/mirabegron", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Mirabegron", "alternateName": [ "Myrbetriq", "Betmiga", "Betanis", "YM-178", "YM178", "beta3-adrenoceptor agonist" ], "description": "Mirabegron is an approved prescription drug, not a research chemical. Astellas Pharma developed it as YM-178 and it was approved by the FDA in 2012 under the brand name Myrbetriq for overactive bladder, with European approval as Betmiga; the US label now also covers neurogenic detrusor overactivity in children aged three and older. It works by activating the beta-3 adrenergic receptor, which relaxes the bladder detrusor muscle. The reason it appears on the research chemical market has nothing to do with bladders. Beta-3 receptors are also the main adrenergic receptors on rodent brown fat, and for decades beta-3 agonists were the leading candidate for a drug that would burn calories by turning on brown adipose tissue. Mirabegron was the first beta-3 agonist available in a form that could test that idea in people. The first test worked. In twelve healthy men, a single oral dose increased brown fat metabolic activity measured by FDG PET-CT in every subject and raised resting metabolic rate by 203 kcal per day, about 13 percent (PMID: 25565203). A four-week open-label study in 14 healthy women found higher brown fat activity and resting energy expenditure with no change in body weight or composition, alongside higher HDL cholesterol, apolipoprotein A-I, adiponectin and improved insulin sensitivity on an intravenous glucose tolerance test (PMID: 31961826). The complication is dose and receptor selectivity. A Canadian group showed that human brown adipocyte thermogenesis is actually driven by the beta-2 receptor, not beta-3, and that mirabegron only raised brown fat thermogenesis when taken at the maximum allowable dose, at which point it also bound beta-1 and beta-2 receptors, producing cardiovascular effects and white fat lipolysis (PMID: 32755608). A meta-analysis of six human studies found increased brown fat activity, resting energy expenditure, body temperature and free fatty acids, but also increased heart rate, diastolic blood pressure and insulin, with no change in brown fat volume or blood glucose (PMID: 38159219). Pharmacology is well characterized because it is a licensed drug. Plasma concentrations peak at three to five hours and decline with a terminal half-life of roughly 32 to 60 hours across two phase 1 studies; exposure is about 40 percent higher in women than men, and steady state is reached within a week (PMID: 23063375). Absorption, metabolism and excretion have been mapped with radiolabeled drug (PMID: 22269146). Anyone taking mirabegron for metabolic reasons is using an approved drug off-label at or near its ceiling dose, where the cardiovascular effects are real and measured. That is a different risk profile from its licensed bladder use, and it needs a prescriber, not a supplier.", "activeIngredient": "Mirabegron", "administrationRoute": "Oral", "mechanismOfAction": "Mirabegron is a selective agonist of the beta-3 adrenergic receptor. In the bladder, beta-3 activation raises cyclic AMP in detrusor smooth muscle and promotes relaxation during the storage phase, which is the licensed mechanism. In adipose tissue, beta-3 stimulation drives lipolysis and, in rodents, uncoupling protein 1 mediated thermogenesis in brown fat. Human data complicate this: brown adipocytes from people express ADRB2 alongside UCP1, and knockdown and receptor-blockade experiments indicate that human brown fat lipolysis and thermogenesis proceed through the beta-2 receptor, with mirabegron raising thermogenesis only at maximal dosing where it also engages beta-1 and beta-2 receptors (PMID: 32755608). The cardiovascular effects seen in metabolic studies, higher heart rate and diastolic blood pressure, follow from that off-target binding (PMID: 38159219).", "dosageForm": "capsule", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is Mirabegron used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "Mirabegron is an approved prescription drug, not a research chemical. Astellas Pharma developed it as YM-178 and it was approved by the FDA in 2012 under the brand name Myrbetriq for overactive bladder, with European approval as Betmiga; the US label now also covers neurogenic detrusor overactivity in children aged three and older. It works by activating the beta-3 adrenergic receptor, which relaxes the bladder detrusor muscle. The reason it appears on the research chemical market has nothing to do with bladders. Beta-3 receptors are also the main adrenergic receptors on rodent brown fat, and for decades beta-3 agonists were the leading candidate for a drug that would burn calories by turning on brown adipose tissue. Mirabegron was the first beta-3 agonist available in a form that could test that idea in people. The first test worked. In twelve healthy men, a single oral dose increased brown fat metabolic activity measured by FDG PET-CT in every subject and raised resting metabolic rate by 203 kcal per day, about 13 percent (PMID: 25565203). A four-week open-label study in 14 healthy women found higher brown fat activity and resting energy expenditure with no change in body weight or composition, alongside higher HDL cholesterol, apolipoprotein A-I, adiponectin and improved insulin sensitivity on an intravenous glucose tolerance test (PMID: 31961826). The complication is dose and receptor selectivity. A Canadian group showed that human brown adipocyte thermogenesis is actually driven by the beta-2 receptor, not beta-3, and that mirabegron only raised brown fat thermogenesis when taken at the maximum allowable dose, at which point it also bound beta-1 and beta-2 receptors, producing cardiovascular effects and white fat lipolysis (PMID: 32755608). A meta-analysis of six human studies found increased brown fat activity, resting energy expenditure, body temperature and free fatty acids, but also increased heart rate, diastolic blood pressure and insulin, with no change in brown fat volume or blood glucose (PMID: 38159219). Pharmacology is well characterized because it is a licensed drug. Plasma concentrations peak at three to five hours and decline with a terminal half-life of roughly 32 to 60 hours across two phase 1 studies; exposure is about 40 percent higher in women than men, and steady state is reached within a week (PMID: 23063375). Absorption, metabolism and excretion have been mapped with radiolabeled drug (PMID: 22269146). Anyone taking mirabegron for metabolic reasons is using an approved drug off-label at or near its ceiling dose, where the cardiovascular effects are real and measured. That is a different risk profile from its licensed bladder use, and it needs a prescriber, not a supplier." } }, { "@type": "Question", "name": "What forms does Mirabegron come in?", "acceptedAnswer": { "@type": "Answer", "text": "Mirabegron is available in capsule form." } }, { "@type": "Question", "name": "How much does Mirabegron cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $99.99 across 1 verified vendor." } }, { "@type": "Question", "name": "How do I compare Mirabegron vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Fmirabegron) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. Mirabegron ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Best price right now $0.03/mg · $99.99 for 3000mg at Disguised Alpha [Buy at Disguised Alpha](https://www.bodyhackguide.co/go/disguised-alpha?utm_source=compound-sticky-bar&utm_campaign=898cd5dc-90cf-4030-9380-7be3706cd9eb&utm_medium=best-price-cta) [Where to buy Mirabegron](/buy/mirabegron) [Mirabegron coupon codes](/coupons/mirabegron) [Mirabegron protocol](/protocol/mirabegron) [Alternatives to Mirabegron](/alternatives-to/mirabegron) [Mirabegron side effects](/side-effects/mirabegron) 1. [Home](/) 3. [Compounds](/compare) 5. Mirabegron ![Mirabegron molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # Mirabegron Pharmaceutical FDA Approved Download PDF Also known as: Myrbetriq, Betmiga, Betanis, YM-178, YM178, beta3-adrenoceptor agonist Mirabegron is an approved prescription drug, not a research chemical. Astellas Pharma developed it as YM-178 and it was approved by the FDA in 2012 under the brand name Myrbetriq for overactive bladder, with European approval as Betmiga; the US label now also covers neurogenic detrusor overactivity in children aged three and older. Half-Life: Terminal half-life about 32 hours in one phase 1 multiple-dose study and about 60 hours in a second, with plasma peaks at three to five hours and steady state within seven days in healthy young and elderly adults (PMID: 23063375) Route: Oral MW: 396.51 g/mol CAS: 223673-61-8 Last reviewed: Sep 7, 2026 [ Pharmaceutical Category ](/wiki#cat-pharmaceutical) FDA Approved Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices1 Related ## Overview ### Best Price Available ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $99.99 60 capsules (50 mg) · capsule [Buy Now](https://disguisedalpha.com/product/mirabegron/?coupon=reddit) Compare 1 vendor ### At A Glance Mechanism Mirabegron is a selective agonist of the beta-3 adrenergic receptor. In the bladder, beta-3 activation raises cyclic AMP in detrusor smooth muscle and promotes relaxation during the storage phase, which is the licensed mechanism. In adipose tissue, beta-3 stimulation drives lipol… Half-Life Terminal half-life about 32 hours in one phase 1 multiple-dose study and about 60 hours in a second, with plasma peaks at three to five hours and steady state within seven days in healthy young and elderly adults (PMID: 23063375) Routes Oral Potential Benefits Increased brown adipose tissue metabolic activity and raised resting metabolic rate by 203 kcal per day in twelve healthy men after a single oral dose (PMID: 25565203) Increased brown fat activity, HDL cholesterol, apolipoprotein A-I and adiponectin and improved insulin sensitivity over four weeks in 14 healthy women (PMID: 31961826) Increased brown fat activity, resting energy expenditure, body temperature and circulating free fatty acids across six human studies in meta-analysis (PMID: 38159219) Reduced adipose tissue myofibroblasts and CXCR2 expression in people with obesity (PMID: 41087927) Reached steady state within seven days with plasma peaks at three to five hours, and about 40 percent higher exposure in women than men, in healthy young and elderly adults (PMID: 23063375) ### Overview Mirabegron is an approved prescription drug, not a research chemical. Astellas Pharma developed it as YM-178 and it was approved by the FDA in 2012 under the brand name Myrbetriq for overactive bladder, with European approval as Betmiga; the US label now also covers neurogenic detrusor overactivity in children aged three and older. It works by activating the beta-3 adrenergic receptor, which relaxes the bladder detrusor muscle. The reason it appears on the research chemical market has nothing to do with bladders. Beta-3 receptors are also the main adrenergic receptors on rodent brown fat, and for decades beta-3 agonists were the leading candidate for a drug that would burn calories by turning on brown adipose tissue. Mirabegron was the first beta-3 agonist available in a form that could test that idea in people. The first test worked. In twelve healthy men, a single oral dose increased brown fat metabolic activity measured by FDG PET-CT in every subject and raised resting metabolic rate by 203 kcal per day, about 13 percent (PMID: 25565203). A four-week open-label study in 14 healthy women found higher brown fat activity and resting energy expenditure with no change in body weight or composition, alongside higher HDL cholesterol, apolipoprotein A-I, adiponectin and improved insulin sensitivity on an intravenous glucose tolerance test (PMID: 31961826). The complication is dose and receptor selectivity. A Canadian group showed that human brown adipocyte thermogenesis is actually driven by the beta-2 receptor, not beta-3, and that mirabegron only raised brown fat thermogenesis when taken at the maximum allowable dose, at which point it also bound beta-1 and beta-2 receptors, producing cardiovascular effects and white fat lipolysis (PMID: 32755608). A meta-analysis of six human studies found increased brown fat activity, resting energy expenditure, body temperature and free fatty acids, but also increased heart rate, diastolic blood pressure and insulin, with no change in brown fat volume or blood glucose (PMID: 38159219). Pharmacology is well characterized because it is a licensed drug. Plasma concentrations peak at three to five hours and decline with a terminal half-life of roughly 32 to 60 hours across two phase 1 studies; exposure is about 40 percent higher in women than men, and steady state is reached within a week (PMID: 23063375). Absorption, metabolism and excretion have been mapped with radiolabeled drug (PMID: 22269146). Anyone taking mirabegron for metabolic reasons is using an approved drug off-label at or near its ceiling dose, where the cardiovascular effects are real and measured. That is a different risk profile from its licensed bladder use, and it needs a prescriber, not a supplier. ### Potential Research Fields Brown adipose tissue Beta-3 adrenergic pharmacology Energy expenditure Urology ## Chemical Information IUPAC Name Not yet available CAS Number 223673-61-8 Molecular Formula C21H24N4O2S Molecular Mass 396.51 g/mol ![Mirabegron molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/9865528/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/9865528) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications Label-based and mechanism-based: the approved product labeling should be consulted, and the documented rises in heart rate and blood pressure make uncontrolled hypertension a clear concern for off-label metabolic use (PMID: 38159219). Exposure is about 40 percent higher in women than in men, which matters for dosing decisions made by a prescriber (PMID: 23063375). Mirabegron inhibits CYP2D6, so interactions with CYP2D6 substrates such as desipramine and metoprolol are documented and require prescriber review. Off-label use for fat loss has not been studied beyond four weeks. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $99.99 Best $/mg $0.0333 Vendors 1 Listings 1 capsule [Sign in for alerts ](/auth) Form Allcapsule Sort Price $/mg Vendor Vendor Product Form Qty Price $/mg Coupon ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK Mirabegron 50 mg capsules (60) capsule 60 capsules (50 mg) ● In Stock $99.99 BEST $0.033 — [Buy](https://disguisedalpha.com/product/mirabegron/?coupon=reddit) Get Mirabegron Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. Current lowest: $99.99 [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Mirabegron. [Sign in](/auth) Current low $99.99 as of Sep 7, 2026 7-day low $99.99 30-day low $99.99 30-day change — baseline building Tracking since Sep 7, 2026 · 1 data point ### Vendors Selling Mirabegron [ ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) #### Disguised Alpha 1 listing · from $99.99 ](/vendor/disguised-alpha) How we score these vendors Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. [View Scorecard](/vendors/scorecard) ### Related Compounds [View All](/wiki) [ ### Albuterol (salbutamol) Pharmaceutical FDA Approved Albuterol, called salbutamol outside the United States, is a beta-2 adrenergic agonist and a standard asthma medicine worldwide. t½ Mean terminal half-life 3.8 hours after intravenous administration in 16 healthy adult men, with absolute oral bioavailability of 44 percent and plasma peaks one to three hours after oral administration (PMID: 3653233) Preclinical View Profile ](/compound/albuterol)[ ### Clascoterone Pharmaceutical Preclinical Clascoterone (brand name Winlevi; development codes CB-03-01 and, for the alopecia formulation, Breezula) is a first-in-class topical androgen receptor (AR) antagonist approved by the U.S. 1188 studies View Profile ](/compound/clascoterone)[ ### Finasteride Pharmaceutical Preclinical Finasteride is an orally-active selective type II 5α-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgenic driver of both benign prostatic hyperplasia (BPH) and androgenetic alopecia (male-pattern hair loss). Preclinical View Profile ](/compound/finasteride)[ ### Meldonium Pharmaceutical Approved (Latvia) Meldonium, sold as Mildronate, was developed at the Latvian Institute of Organic Synthesis (PMID: 12242052) and is a licensed cardiovascular medicine in Latvia and a number of eastern European and post-Soviet countries. t½ Not a single simple value: in 32 healthy athlete volunteers taking oral meldonium for three weeks, plasma took several days to reach steady state and urinary elimination continued for several months after the last dose, because tissue clearance depends on slow diffusion rather than transport (PMID: 30328291) Preclinical View Profile ](/compound/meldonium)[ ### Tropisetron Pharmaceutical Approved (Japan) Tropisetron, coded ICS 205-930 during development and marketed as Navoban, is a serotonin 5-HT3 receptor antagonist approved as an antiemetic in Japan and in many other countries outside the United States, with ATC code A04AA03 (KEGG DRUG D02041, D02130). t½ About 5.7 h after a single 5 mg oral capsule and 5.6 h after 2 mg intravenously in 18 healthy volunteers; oral bioavailability averaged 0.60 with a range of 0.27 to 0.99 and was inversely related to CYP2D6 activity (PMID: 11736884) Preclinical View Profile ](/compound/tropisetron) [ View Full Dosage Guide → Protocols, calculator & safety for Mirabegron ](/guides/dosage/mirabegron) ### Best Price ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $99.99 [Buy Now](https://disguisedalpha.com/product/mirabegron/?coupon=reddit) 1 vendors · 1 listings ### Research Score 30 0 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Half-Life Terminal half-life about 32 hours in one phase 1 multiple-dose study and about 60 hours in a second, with plasma peaks at three to five hours and steady state within seven days in healthy young and elderly adults (PMID: 23063375) Molecular Weight 396.51 g/mol Administration Oral CAS Number 223673-61-8 Trial Phase FDA Approved 0 [Full Dosage Guide](/guides/dosage/mirabegron)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is Mirabegron used for in research? Mirabegron is an approved prescription drug, not a research chemical. Astellas Pharma developed it as YM-178 and it was approved by the FDA in 2012 under the brand name Myrbetriq for overactive bladder, with European approval as Betmiga; the US label now also covers neurogenic detrusor overactivity in children aged three and older. It works by activating the beta-3 adrenergic receptor, which relaxes the bladder detrusor muscle. The reason it appears on the research chemical market has nothing to do with bladders. Beta-3 receptors are also the main adrenergic receptors on rodent brown fat, and for decades beta-3 agonists were the leading candidate for a drug that would burn calories by turning on brown adipose tissue. Mirabegron was the first beta-3 agonist available in a form that could test that idea in people. The first test worked. In twelve healthy men, a single oral dose increased brown fat metabolic activity measured by FDG PET-CT in every subject and raised resting metabolic rate by 203 kcal per day, about 13 percent (PMID: 25565203). A four-week open-label study in 14 healthy women found higher brown fat activity and resting energy expenditure with no change in body weight or composition, alongside higher HDL cholesterol, apolipoprotein A-I, adiponectin and improved insulin sensitivity on an intravenous glucose tolerance test (PMID: 31961826). The complication is dose and receptor selectivity. A Canadian group showed that human brown adipocyte thermogenesis is actually driven by the beta-2 receptor, not beta-3, and that mirabegron only raised brown fat thermogenesis when taken at the maximum allowable dose, at which point it also bound beta-1 and beta-2 receptors, producing cardiovascular effects and white fat lipolysis (PMID: 32755608). A meta-analysis of six human studies found increased brown fat activity, resting energy expenditure, body temperature and free fatty acids, but also increased heart rate, diastolic blood pressure and insulin, with no change in brown fat volume or blood glucose (PMID: 38159219). Pharmacology is well characterized because it is a licensed drug. Plasma concentrations peak at three to five hours and decline with a terminal half-life of roughly 32 to 60 hours across two phase 1 studies; exposure is about 40 percent higher in women than men, and steady state is reached within a week (PMID: 23063375). Absorption, metabolism and excretion have been mapped with radiolabeled drug (PMID: 22269146). Anyone taking mirabegron for metabolic reasons is using an approved drug off-label at or near its ceiling dose, where the cardiovascular effects are real and measured. That is a different risk profile from its licensed bladder use, and it needs a prescriber, not a supplier. What forms does Mirabegron come in? Mirabegron is available in capsule form. How much does Mirabegron cost? Prices start at $99.99 across 1 verified vendor. How do I compare Mirabegron vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### Albuterol (salbutamol) Pharmaceutical FDA Approved Albuterol, called salbutamol outside the United States, is a beta-2 adrenergic agonist and a standard asthma medicine worldwide. t½ Mean terminal half-life 3.8 hours after intravenous administration in 16 healthy adult men, with absolute oral bioavailability of 44 percent and plasma peaks one to three hours after oral administration (PMID: 3653233) Preclinical View Profile ](/compound/albuterol)[ ### Clascoterone Pharmaceutical Preclinical Clascoterone (brand name Winlevi; development codes CB-03-01 and, for the alopecia formulation, Breezula) is a first-in-class topical androgen receptor (AR) antagonist approved by the U.S. 1188 studies View Profile ](/compound/clascoterone)[ ### Finasteride Pharmaceutical Preclinical Finasteride is an orally-active selective type II 5α-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgenic driver of both benign prostatic hyperplasia (BPH) and androgenetic alopecia (male-pattern hair loss). Preclinical View Profile ](/compound/finasteride)[ ### Meldonium Pharmaceutical Approved (Latvia) Meldonium, sold as Mildronate, was developed at the Latvian Institute of Organic Synthesis (PMID: 12242052) and is a licensed cardiovascular medicine in Latvia and a number of eastern European and post-Soviet countries. t½ Not a single simple value: in 32 healthy athlete volunteers taking oral meldonium for three weeks, plasma took several days to reach steady state and urinary elimination continued for several months after the last dose, because tissue clearance depends on slow diffusion rather than transport (PMID: 30328291) Preclinical View Profile ](/compound/meldonium)[ ### Tropisetron Pharmaceutical Approved (Japan) Tropisetron, coded ICS 205-930 during development and marketed as Navoban, is a serotonin 5-HT3 receptor antagonist approved as an antiemetic in Japan and in many other countries outside the United States, with ATC code A04AA03 (KEGG DRUG D02041, D02130). t½ About 5.7 h after a single 5 mg oral capsule and 5.6 h after 2 mg intravenously in 18 healthy volunteers; oral bioavailability averaged 0.60 with a range of 0.27 to 0.99 and was inversely related to CYP2D6 activity (PMID: 11736884) Preclinical View Profile ](/compound/tropisetron) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-mirabegron) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋